# A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT05431179** · PHASE3 · WITHDRAWN · sponsor: **Oncternal Therapeutics, Inc**

## Conditions studied

- Lymphoma, Mantle-Cell
- Lymphoma
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Immune System Diseases
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell

## Interventions

- **DRUG:** Zilovertamab
- **DRUG:** Ibrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05431179
- **Lead sponsor:** Oncternal Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431179, "A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05431179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*